导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.33% | 1238/4773 |
| 近一周 | -1.96% | 966/5462 |
| 近一月 | -3.57% | 1838/5421 |
| 近一季 | -6.52% | 2122/5209 |
| 近半年 | -1.08% | 1471/4920 |
| 近一年 | 7.75% | 1264/4366 |
| 近两年 | 51.00% | 1439/2954 |
| 近三年 | 36.08% | 831/2253 |
| 成立以来 | 56.05% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.40% 1289/4961 |
12.25% 2201/5312 |
- - |
- - |
| 2025 | 19.30% 2231/4813 |
0.77% 1773/3635 |
2.74% 1394/4076 |
13.51% 2984/4524 |
1.52% 1347/4813 |
| 2024 | 16.68% 780/3463 |
4.36% 458/2808 |
0.37% 628/3014 |
14.85% 1895/3129 |
-3.00% 2228/3463 |
| 2023 | -9.19% 1125/2656 |
3.47% 1188/2280 |
-4.24% 1101/2385 |
-2.46% 681/2515 |
-6.04% 1606/2655 |
| 2022 | -19.85% 908/2207 |
-13.21% 716/1919 |
6.68% 634/2016 |
-12.70% 764/2113 |
-0.85% 1651/2208 |
| 2021 | 4.51% 573/1822 |
-0.39% 360/1255 |
7.00% 708/1330 |
-2.34% 566/1466 |
0.41% 1119/1822 |
| 2020 | 38.87% 345/1250 |
-10.21% 766/1028 |
14.98% 525/1067 |
20.47% 52/1164 |
11.64% 530/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 新华沪深300指数增强A VS. 长安沪深300非周期A(740101) |